StockData
LENSAR, Inc. logo

LENSAR, Inc. (LNSR) stock

LNSRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/3022% below fair value
$4.91−0.38 (-7.18%)

Close on Nov 17, 2026Market cap $60.32MP/E –Yield –

LENSAR, Inc. grew revenue 3.3% to $60.26M over the twelve months to Jun 30, 2026. Free cash flow was -$14.91M. At the latest close the market valued the company at $60.32M.

Revenue
$60.26M
+3.3% vs. a year earlier
Operating income
-$8.13M
TTM Q2 2026
Free cash flow
-$14.91M
FY2025
EPS, diluted
-$0.33
TTM Q2 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$60.32M
P/E ratio
–
Price to sales
1.00
Price to book
4.05
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$60.26M
Net income
$34.70M
EPS, diluted
-$0.33
Free cash flow
-$14.91M
Book value per share
$0.65
Diluted shares
23M

Trading

Next earnings
Mar 30, 2027 (estimated, before the open)
Previous close
$5.29
Open
$5.27
Day's range
$4.89 – $5.40
Volume
111,964
Average volume (20 days)
74,543
Index membership
Russell 2000 (since Jun 2025)
52-week range
$4.30 – $12.94
RSI (14 days)
36.1
Volatility (1 year)
69.5%
Relative volume
1.22×

Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2020, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodLNSRS&P 500DifferenceLNSR per yearS&P 500 per year
1 month-15.3%-4.0%−11.3 pts
3 months-39.3%-5.0%−34.3 pts
Year to date-57.8%+8.2%−66.0 pts
1 year-50.2%+11.2%−61.4 pts
3 years+124.2%+68.5%+55.7 pts+30.9%+19.0%
5 years-32.8%+67.3%−100.1 pts-7.7%+10.8%

Eight years at a glance

Fiscal years 2018 to 2025 and trailing twelve months, USD

Revenue

$60.26M+3.3% YoY

Gross profit

$29.13M+5.8% YoY

Operating income

-$8.13M

Net income

$34.70M

EPS, diluted

-$0.33

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Lensar filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Lensar

Surgical & Medical Instruments & Apparatus

LENSAR, Inc. is a commercial-stage medical device company that develops, designs, and markets advanced femtosecond laser systems. Its primary offerings include the LENSAR Laser System and the next-generation ALLY Robotic Cataract Laser System, which integrate proprietary technologies such as advanced imaging and procedural planning to support ophthalmic procedures. The company’s systems are designed for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its customer base consists of ophthalmic cataract surgeons, practices, and ambulatory surgery centers.

Company profile, executives and history

Lensar stock: common questions

What is Lensar's stock price?

LNSR closed at $4.91 on Nov 17, 2026, down 7.18% on the day. Over the past 52 weeks it traded between $4.30 and $12.94.

What is Lensar's market cap?

Lensar was worth $60.32M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is LNSR's P/E ratio?

Lensar lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.33), so it has no meaningful P/E ratio.

How much revenue does Lensar make?

Lensar reported revenue of $60.26M for the twelve months to Jun 30, 2026, up 3.3% from a year earlier.

Does Lensar pay a dividend?

No. Lensar has not paid a cash dividend over the last twelve months.

When does Lensar report earnings next?

Lensar is expected to report Q4 FY2026 results on Mar 30, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.

How has LNSR stock performed over the past year?

Including dividends, LNSR returned -50.2% over the past year, against +11.2% for the S&P 500.

Who are Lensar's competitors?

Companies most similar to Lensar by business, industry and size include SGHT, SSII, CVRX, APYX, TELA.

See a number that looks wrong?